Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed acute myeloid leukemia or acute lymphoblastic leukemia (ALL)~  * Relapsed or refractory disease~* Patients with Philadelphia chromosome-positive (Ph+) ALL refractory to BCR/ABL inhibitors are eligible~* Patients who have relapsed after prior autologous or allogenic stem cell transplant are eligible~* No active CNS disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Serum albumin ≥ 3 g/dL~* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN if transaminase elevation is due to leukemic involvement)~* Bilirubin ≤ 1.5 times ULN~* Creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min~* Potassium ≥ lower limit of normal (LLN)~* Phosphorous ≥ LLN~* Serum total calcium (corrected for serum albumin) or serum ionized calcium ≥ LLN~* Magnesium ≥ LLN~* Thyroid stimulating hormone and free T4 normal (thyroid hormone replacement therapy allowed)~* LVEF ≥ LLN by MUGA or ECHO~* No impaired cardiac function, including any of the following:~  * QTc \> 450 msec~ * Congenital long QT syndrome~ * History of sustained ventricular tachycardia~ * History of ventricular fibrillation or torsades de pointes~ * Bradycardia (i.e., heart rate \< 50 beats per minute)~    * Pacemaker allowed provided heart rate ≥ 50 beats per minute~ * Myocardial infarction or unstable angina within the past 6 months~ * New York Heart Association class III-IV congestive heart failure~ * Right bundle branch block and left anterior hemiblock (bifascicular block)~* No uncontrolled hypertension~* No unresolved diarrhea \> CTCAE grade 1~* No impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-barrier contraception during and for 3 months after completion of study treatment~* No other primary malignancy within the past 5 years, other than curatively treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin~* No HIV or hepatitis C positivity~* No other concurrent severe and/or uncontrolled medical condition~* No significant history of non-compliance to medical regimens or inability to give reliable informed consent~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy~* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy~* More than 4 weeks since prior valproic acid~* No other prior treatment with a histone deacetylase inhibitor~* No concurrent medication that may cause QTc prolongation or induce torsades de pointes~* No concurrent CYP3A4 inhibitors~* No concurrent grapefruit, grapefruit juice, or Seville (sour) oranges~* No concurrent radiotherapy~* No other concurrent anticancer therapy or investigational therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (panobinostat) (Type: EXPERIMENTAL): Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy